About GPO   |   Newsroom/Media   |   Congressional Relations   |   Inspector General   |   Careers   |   Contact   |   askGPO   |   Help  
 
Home   |   Customers   |   Vendors   |   Libraries  

The Electronic Code of Federal Regulations (e-CFR) is a regularly updated, unofficial editorial compilation of CFR material and Federal Register amendments produced by the National Archives and Records Administration's Office of the Federal Register (OFR) and the Government Printing Office.

Parallel Table of Authorities and Rules for the Code of Federal Regulations and the United States Code
Text | PDF

Find, review, and submit comments on Federal rules that are open for comment and published in the Federal Register using Regulations.gov.

Purchase individual CFR titles from the U.S. Government Online Bookstore.

Find issues of the CFR (including issues prior to 1996) at a local Federal depository library.

[1]
 
 

Electronic Code of Federal Regulations

blue pill

e-CFR Data is current as of October 22, 2014

Title 21Chapter ISubchapter DPart 314


TITLE 21—Food and Drugs

CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED)

SUBCHAPTER D—DRUGS FOR HUMAN USE

PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG

rule

Subpart A—GENERAL PROVISIONS

§314.1
Scope of this part.
§314.2
Purpose.
§314.3
Definitions.
rule

Subpart B—APPLICATIONS

§314.50
Content and format of an application.
§314.52
Notice of certification of invalidity or noninfringement of a patent.
§314.53
Submission of patent information.
§314.54
Procedure for submission of an application requiring investigations for approval of a new indication for, or other change from, a listed drug.
§314.55
Pediatric use information.
§314.60
Amendments to an unapproved application, supplement, or resubmission.
§314.65
Withdrawal by the applicant of an unapproved application.
§314.70
Supplements and other changes to an approved application.
§314.71
Procedures for submission of a supplement to an approved application.
§314.72
Change in ownership of an application.
§314.80
Postmarketing reporting of adverse drug experiences.
§314.81
Other postmarketing reports.
§314.90
Waivers.
§314.91
Obtaining a reduction in the discontinuance notification period.
rule

Subpart C—ABBREVIATED APPLICATIONS

§314.92
Drug products for which abbreviated applications may be submitted.
§314.93
Petition to request a change from a listed drug.
§314.94
Content and format of an abbreviated application.
§314.95
Notice of certification of invalidity or noninfringement of a patent.
§314.96
Amendments to an unapproved abbreviated application.
§314.97
Supplements and other changes to an approved abbreviated application.
§314.98
Postmarketing reports.
§314.99
Other responsibilities of an applicant of an abbreviated application.
rule

Subpart D—FDA ACTION ON APPLICATIONS AND ABBREVIATED APPLICATIONS

§314.100
Timeframes for reviewing applications and abbreviated applications.
§314.101
Filing an application and receiving an abbreviated new drug application.
§314.102
Communications between FDA and applicants.
§314.103
Dispute resolution.
§314.104
Drugs with potential for abuse.
§314.105
Approval of an application and an abbreviated application.
§314.106
Foreign data.
§314.107
Effective date of approval of a 505(b)(2) application or abbreviated new drug application under section 505(j) of the act.
§314.108
New drug product exclusivity.
§314.110
Complete response letter to the applicant.
§314.120
[Reserved]
§314.122
Submitting an abbreviated application for, or a 505(j)(2)(C) petition that relies on, a listed drug that is no longer marketed.
§314.125
Refusal to approve an application.
§314.126
Adequate and well-controlled studies.
§314.127
Refusal to approve an abbreviated new drug application.
§314.150
Withdrawal of approval of an application or abbreviated application.
§314.151
Withdrawal of approval of an abbreviated new drug application under section 505(j)(5) of the act.
§314.152
Notice of withdrawal of approval of an application or abbreviated application for a new drug.
§314.153
Suspension of approval of an abbreviated new drug application.
§314.160
Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.
§314.161
Determination of reasons for voluntary withdrawal of a listed drug.
§314.162
Removal of a drug product from the list.
§314.170
Adulteration and misbranding of an approved drug.
rule

Subpart E—HEARING PROCEDURES FOR NEW DRUGS

§314.200
Notice of opportunity for hearing; notice of participation and request for hearing; grant or denial of hearing.
§314.201
Procedure for hearings.
§314.235
Judicial review.
rule

Subpart F—[RESERVED]

rule

Subpart G—MISCELLANEOUS PROVISIONS

§314.410
Imports and exports of new drugs.
§314.420
Drug master files.
§314.430
Availability for public disclosure of data and information in an application or abbreviated application.
§314.440
Addresses for applications and abbreviated applications.
§314.445
Guidance documents.
rule

Subpart H—ACCELERATED APPROVAL OF NEW DRUGS FOR SERIOUS OR LIFE-THREATENING ILLNESSES

§314.500
Scope.
§314.510
Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
§314.520
Approval with restrictions to assure safe use.
§314.530
Withdrawal procedures.
§314.540
Postmarketing safety reporting.
§314.550
Promotional materials.
§314.560
Termination of requirements.
rule

Subpart I—APPROVAL OF NEW DRUGS WHEN HUMAN EFFICACY STUDIES ARE NOT ETHICAL OR FEASIBLE

§314.600
Scope.
§314.610
Approval based on evidence of effectiveness from studies in animals.
§314.620
Withdrawal procedures.
§314.630
Postmarketing safety reporting.
§314.640
Promotional materials.
§314.650
Termination of requirements.


For questions or comments regarding e-CFR editorial content, features, or design, email ecfr@nara.gov.
For questions concerning e-CFR programming and delivery issues, email webteam@gpo.gov.